Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The clinical hypothesis of this study is that the addition of Panitumumab to the first line treatment combination of docetaxel plus cisplatin will provide benefit to patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
DRUG: panitumumab + docetaxel + cisplatino
Objective response rate, To estimate the objective response rate in patients treated with docetaxel, cisplatin and panitumumab as first-line treatment in advanced gastric or gastroesophageal junction adenocarcinoma., 3 years
Disease control rate, 3 years|Duration of response, 3 years|Time to response, 3 years|Time to progression, 3 years|Time to treatment failure, 3 years|Duration of stable disease, 3 years|Progression free survival, 3 years|Overall survival, 3 years|Safety profile, To describe the safety profile of this combination therapy in the 1st-line setting including the incidence of AE's and changes in laboratory parameters., 3 years|Exploratory Objectives, To investigate the predictive potential of different biomarkers on efficacy and/or safety endpoints., 3 years
The clinical hypothesis of this study is that the addition of Panitumumab to the first line treatment combination of docetaxel plus cisplatin will provide benefit to patients with advanced gastric or gastroesophageal junction adenocarcinoma.